Abstract
Various preclinical studies have stated that members of the MYC transcription factor family (C-myc, L-myc and N-myc) are involved in disease progression and may represent promising therapeutic targets in small cell lung cancer (SCLC). However, there is limited knowledge on the clinical significance of MYC family members in surgically resected SCLC specimens. Our aim was to evaluate the expression and prognostic value of MYC family members in an international cohort of surgically resected SCLC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
